Jacobs Levy Equity Management
ELTX icon

Jacobs Levy Equity Management’s Elicio Therapeutics ELTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,524
Closed -$131K – 1019
2021
Q4 		$131K Buy
+4,524
New +$229K ﹤0.01% 951
2021
Q3 		– Sell
-5,715
Closed -$744K – 1059
2021
Q2 		$744K Buy
+5,715
New +$824K 0.01% 801

Other funds holding ELTX

NCM
Nantahala Capital Management New Canaan, Connecticut $3B AUM 119.43% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
LSAG
Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jacobs Levy Equity Management's ELTX Position: Q1 2022 in Review

Jacobs Levy Equity Management sold out of Elicio Therapeutics (ELTX) in Q1 2022, closing a stake of 4,524 shares — an estimated $131K sold.

Jacobs Levy Equity Management first reported a position in ELTX in Q2 2021 and held it in 2 quarters. The position peaked at $744K in Q2 2021. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2022.

  • Jacobs Levy Equity Management reported no remaining Elicio Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 4,524 Elicio Therapeutics shares in Q1 2022, an estimated $131K.
  • Jacobs Levy Equity Management first reported a position in Elicio Therapeutics in Q2 2021 and held it in 2 quarters.
  • Jacobs Levy Equity Management's Elicio Therapeutics position peaked at $744K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2022, filed 16 May 2022.